Revance Therapeutics (RVNC) Misses Q4 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 inches lower as Middle East tensions outweigh tech gains
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Aegis Capital Reiterates Buy on Revance Therapeutics (RVNC) Following 4Q Report
February 28, 2017 8:18 AM ESTAegis Capital reiterated a Buy rating and $28.00 price target on Revance Therapeutic (NASDAQ: RVNC) following the company's 4Q earnings report. Revance reiterated its prior guidance for cash burn of $102 to $112 mil for 2017.
Analyst Difei Yang commented, "Yesterday, Revance Therapeutics announced fourth quarter... More
